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468Background: The detrimental effect of active smoking on operative outcome after coronary artery bypass graft-
ing (CABG) is still debated and smoking cessation programs are usually deferred until after surgery. The poten-
tial benefit from smoking cessation on postoperative outcomes is investigated in this study.
Methods:A retrospective analysis on a large cohort of patients who underwent CABG at a single institution was
performed. Generalized boosted regression modeling was used to estimate the multinominal propensity scores
for smoking status categories and the average treatment effect on the treated was calculated for all outcomes of
interest.
Results: A total of 6113 patients who underwent isolated CABG for the first time were included. At baseline,
there were 640 (10.4%) current smokers, 3309 (54.1%) ex-smokers, and 2164 (35.3%) nonsmokers. Multilevel
propensity score weighted analysis showed a beneficial effect of smoking cessation compared with current
smoking, which increased the risk for all major pulmonary complications (odds ratio [OR], 1.54; 95% confi-
dence interval [CI], 1.13-2.10; P ¼ .006), including reintubation (OR, 1.95; 95% CI, 1.17-3.25; P ¼ .01),
full tracheostomy (OR, 3.04; 95% CI, 1.49-6.18; P ¼ .002), lung infection/consolidation (OR, 1.44; 95%
CI, 1.02-2.02; P ¼ .03). Although smoking cessation did not significantly improve other outcomes, it was asso-
ciated with a nonsignificant trend toward a decreased risk for in-hospital mortality (OR, 1.83; 95% CI,
0.85-3.91; P ¼ .1).
Conclusions: This study showed that smoking cessation before CABG reduced the risk of serious pulmonary
complications. The present findings indicate that embarking on a smoking cessation program should not be de-
ferred until after surgery. (J Thorac Cardiovasc Surg 2014;148:468-74)Tobacco smoking remains the leading cause of preventable
morbidity and mortality in the world1 and smoking cessa-
tion is associated with important benefits.2 In addition to
the general health risks associated with smoking, it has
been shown that smokers are more likely to have postoper-
ative complications including delayed wound healing, pul-
monary complications, and mortality.3
Smoking cessation has been consistently shown to offer
important benefits in reducing complications in patients un-
dergoing noncardiac surgery.3
Cigarette smoking is a major contributor to the risk of
coronary heart disease4 and a large number of active
smokers are referred for coronary artery bypass graftinge Department of Cardiac Surgery, Royal Brompton & Harefield NHS Foun-
Trust, Harefield Hospital, London, United Kingdom.
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The Journal of Thoracic and Cardiovascular Surg(CABG) worldwide. Although smoking cessation after
CABG has been found to improve late outcomes,5,6
cardiac surgeons continue to debate whether patients who
have stopped smoking should wait for a definite period of
time before undergoing surgery.7 Few limited studies have
investigated the effect of active smoking on CABG opera-
tive outcomes and discordant results have been reported.8-12
The main risk scoring systems in cardiac surgery such as
EuroSCORE and STS score failed to investigate the effect
of active smoking on operative mortality.13 As a conse-
quence, active smoking at the time of surgery is not
commonly perceived as a main risk factor for operative
morbidity and mortality, and smoking cessation programs
are usually deferred until after surgery.
Therefore, we investigated the potential benefit of smok-
ing cessation on operative outcomes after CABG by con-
ducting a detailed analysis on a large cohort of patients
from a single institution.PATIENTS AND METHODS
Study Population
The study was conducted in accordancewith the principles of the Decla-
ration of Helsinki.
Prospectively collected data from the institutional surgical database
(PATS; Dendrite Clinical Systems, Ltd, Oxford, UK) were analyzedery c August 2014
Abbreviations and Acronyms
ATT ¼ average treatment effect on the treated
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
GBM ¼ generalized boosted regression modeling
IR ¼ incomplete revascularization
NYHA ¼ New York Heart Association
POAF ¼ postoperative atrial fibrillation
SWI ¼ sternal wound infection
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range of preoperative, intraoperative, and hospital postoperative variables
(including complications and mortality) for all patients undergoing cardiac
surgery in our institution. The data are collected and reported in accordance
with the Society for Cardiothoracic Surgery in Great Britain & Ireland
database criteria. The database is maintained by a team of full-time clinical
information analysts, who are responsible for continuous prospective data
collection as part of a continuous audit process. Data collection is validated
regularly. Patients undergoing isolated first-time CABG fromApril 2001 to
May 2013 were included in the present analysis.
Patients were scheduled for surgery according to internal guidelines for
the scheduling of patients on the waiting list: emergency (within 24 hours),
very urgent (0-4 weeks), urgent (4-8 weeks), soon (8-12 weeks), and
routine (18 weeks from referral to surgery). Patients on the waiting list
complaining of worsening of symptoms were reviewed in the clinic by
the allocated consultant or given a theatre slot with the first available
consultant as appropriate.
Patients were queried about their smoking habits at index admission.
The study population was divided into 3 groups based on smoking habits:
(1) never smoked, defined as patients who had never smoked cigarettes
regularly; (2) ex-smokers, defined as those who had quit smoking at least
4 weeks before the index procedure; and (3) current smokers, defined as
those who smoked within 4 weeks before the index procedure. Four weeks
was chosen as the smoking cessation cut-off according to a previous meta-
analysis of randomized controlled trials enrolling patients undergoing
noncardiac surgery demonstrating that trials of at least 4 weeks’ smoking
cessation had significantly larger treatment effects on postoperative com-
plications than shorter trials.3
Smoking cessation services were provided for all prospective surgical
candidates and brief intervention counseling was offered during surgical
preadmission checks. All smokers and ex-smokers (within 5 years) had pre-
operative pulmonary function testing. When an airflow obstruction
(defined as an FEV1/FVC ratio<0.7, where FEV1 is forced expiratory vol-
ume in the first second of expiration and FVC is forced vital capacity, and a
predicted FEV1<80%) was demonstrated, bronchodilators were started
before surgery. During the study period, no case was delayed to achieve
a period of smoking cessation.
Outcomes
The following postoperative complications were investigated: major
lung complications including full tracheostomy, reintubation, lung infec-
tion/consolidation; low cardiac output syndrome defined as the need for
inotropes and/or an intra-aortic balloon pump after surgery, need for renal
replacement therapy, a postoperative cerebrovascular accident, both tran-
sient or permanent, reexploration for bleeding, sternal rewiring for insta-
bility, sternal wound infection (SWI) either superficial or deep,
postoperative atrial fibrillation (POAF), pleural effusion requiring
drainage, prolonged postoperative hospital stay (defined as length of stay
75th percentile of postoperative stay length distribution), and in-
hospital mortality.The Journal of Thoracic and CaStatistical Analysis
For baseline characteristics, variables were summarized as the mean 
standard deviation for continuous variables and number and percentage for
categorical variables. The standardized mean differencewas used to quantify
differences in means or prevalence among groups using ex-smokers as refer-
ence; a value>0.10 representedmeaningful imbalance in a given covariate.14
The following risk factors were investigated: age, gender, diabetes mel-
litus, body mass index (BMI) 30 kg/m2, renal impairment defined as a
baseline serum creatinine level 200 mmol/L, previous myocardial infarc-
tion, history of congestive heart failure, chronic obstructive pulmonary dis-
ease (defined as long-term use of bronchodilators or steroids for lung
disease or evidence of airflow obstruction on preoperative pulmonary func-
tion testing), history of cerebrovascular accident, functional New York Heart
Association (NYHA) class III or IV, reduced left ventricular ejection frac-
tion (<50%), peripheral vascular disease, nonelective surgery, use of cardio-
pulmonary bypass, number of grafts, and incomplete revascularization.
The incidence of postoperative complications was compared among
groups by means of the c2 test or analysis of variance for continuous vari-
ables. To separate the effect of smoking cessation on outcomes from
observed confounding factors that influenced smoking status at the time
of surgery, nonparsimonious, generalized boosted regression modeling
(GBM) was implemented to estimate the multinominal propensity scores
(number of interactions ¼ 3000) for smoking status categories including
all preoperative risk factors. This method relies on tree-based regression
models that are built in an iterative fashion. As the iterations or number
of regression trees added to the model increases, the model becomes
more complex. However, at some point, more complex models typically
result in worse balance and therefore are less useful in a propensity score
weighting context. The key assumption that each unit had a nonzero prob-
ability of belonging to each group was assessed by the overlap of the empir-
ical propensity score distributions. Balance among smoking status groups
was assessed by means of comparisons of effect size standardized as the
mean difference of the effect size before and after weighting.
The propensity score weights were used as case weights in a generalized
linear logistic model to estimate the average treatment effect on the treated
(ATT) for all outcomes of interest.13 In brief, the ATTanswers the question
of how the average outcome would change if everyone who received sur-
gery without smoking cessation had instead received surgery after a smok-
ing cessation period. These models estimated the odds ratio (OR) and 95%
confidence interval (CI) for each smoking status category using ex-smokers
as the treatment group.
The following programs were used for the statistical analysis: R version
2.15.2 (R Foundation for Statistical Computing, Vienna, Austria; http://
www.R-project.org/), twang (Toolkit for weighting and analysis of
nonequivalent groups, R package version 1.3-18; http://CRAN.R-projec-
t.org/package¼twang), and survey packages (Survey: analysis of complex
survey samples, R package version 3.28-2; http://carn.r-project.org).RESULTS
Baseline Characteristics
A total of 6113 patients who underwent isolated first-time
CABG were included. At baseline, the were 640 (10.4%)
current smokers, 3309 (54.1%) ex-smokers, and 2164
(35.3%) nonsmokers. Baseline characteristics stratified by
smoking status are shown in Table 1. Eight of 16 variables
were different among smoking status groups (standardized
mean difference>0.1) including age, female gender, previ-
ous myocardial infarction, chronic obstructive pulmonary
disease, reduced left ventricular ejection fraction, periph-
eral vascular disease, nonelective indication, and the use
of cardiopulmonary bypass.rdiovascular Surgery c Volume 148, Number 2 469
TABLE 1. Baseline characteristics
Ex-smokers
(N ¼ 3309)
Never smokers
(N ¼ 2164)
Current smokers
(N ¼ 640)
Standardized
difference
(never smokers
vs ex-smokers)
Standardized
difference
(current smokers
vs ex-smokers)
n % n % n %
Before
weighting
After
weighting
Before
weighting
After
weighting
Age 70 y 1307 39.5 878 40.6 99 15.6 0.03 0.006 0.66 0.08
Female 112 3.4 151 7 16 2.6 0.19 0.005 0.05 0.01
Diabetes 787 23.8 545 25.2 131 20.5 0.03 0.005 0.09 0.02
BMI 30 kg/m2 1012 30.6 566 26.2 183 28.6 0.09 0.02 0.017 0.02
Renal impairment 79 2.4 51 2.4 7 1.2 0.001 0.04 0.07 0.04
Previous MI 1393 42.1 757 35 280 43.9 0.14 0.027 0.03 0.007
CHF 231 7 123 5.7 42 6.7 0.04 0.03 0.03 0.06
COPD 347 10.5 142 6.6 92 14.5 0.13 0.05 0.08 0.02
Previous CVA 214 6.48 101 4.68 46 7.34 0.08 0.02 0.03 0
NYHA III-IV 956 28.9 605 28 190 29.8 0.02 0.02 0.006 0
LVEF<50% 698 21.1 359 16.6 144 22.5 0.11 0.03 0.014 0.01
PVD 322 9.74 103 4.76 77 12.1 0.15 0.06 0.069 0.007
LMD 906 27.4 551 25.5 173 27.1 0.03 0.02 0.023 0.006
Emergency or very urgent 916 27.7 629 29.1 197 30.9 0.05 0 0.1 0.02
CPB 1012 30.6 566 26.2 183 28.6 0.1 0.001 0.002 0.01
No. grafts/patient (mean, SD) 2.6 0.8 2.6 0.8 2.6 0.8 0.01 0.006 0.03 0.04
IR 635 19.2 408 18.9 110 17.2 0.01 0.01 0.05 0.04
BMI, Body mass index;MI, myocardial infarction; CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; NYHA, New York
Heart Association; LVEF, left ventricular ejection fraction; PVD, peripheral vascular disease; LMD, left main disease; CPB, cardiopulmonary bypass; IR, incomplete revascu-
larization; SD, standard deviation.
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The incidence of postoperative complications was as fol-
lows: major lung complication 847 (13%), including rein-
tubation 265 (4.1%), full tracheostomy 102 (1.6%), and
lung infection/consolidation 847 (13.8%); low output syn-
drome 1514 (24.7%); need for renal replacement therapy
278 (4.5%); perioperative cerebrovascular accident 72
(1.1%); reexploration for bleeding 253 (4.1%); sternal re-
wiring for instability 176 (2.8%), SWI 385 (6.2%);
POAF 1271 (21.2%); pleural effusion requiring drainage
285 (4.6%); hospital death 129 (2.1%). Median postopera-
tive length of stay was 7 days (interquartile range, 6-10).
Prolonged hospital stay (10 days) occurred in 1604 pa-
tients (26.2%). The rate of postoperative complications
stratified by smoking status is shown in Table 2. The crude
incidence of postoperative complications did not differ
significantly among smoking status groups apart from the
incidence of POAF, which was decreased among current
smokers. The rate of lung infection/consolidation was
slightly increased among current smokers (P ¼ .047) but
not the incidence of reintubation (P ¼ .25), full tracheos-
tomy (P ¼ .1), and overall incidence of major lung compli-
cation (P ¼ .1).
Effect of Smoking on Operative Outcomes
To separate the effect of smoking cessation on outcomes
from observed confounding factors, multinominal propen-
sity scores were then calculated. Balance measures were470 The Journal of Thoracic and Cardiovascular Surgoptimized by GBM with substantially fewer than 3000 iter-
ations (Figure 1). A total of 2280 iterations minimized the
average effect size difference between current smokers
and ex-smokers for the covariates (average difference
before weighting, 0.08; after weighting, 0.02). A total of
2720 iterations minimized the average effect size difference
between never smokers and ex-smokers (average difference
before weighting, 0.07; after weighting, 0.02). All covari-
ates were well balanced after weighting (Table 1) and there
was good overlap for propensity scores among groups
(Figure 2).
Multilevel propensity score weighted analysis for the
ATTestimate (Table 3) showed a beneficial effect of smok-
ing cessation compared with current smoking, which
increased the risk for all major pulmonary complications
(OR, 1.54; 95% CI, 1.13-2.10; P¼ .006) including reintu-
bation (OR, 1.95; 95% CI, 1.17-3.25; P¼ .01), full trache-
otomy (OR, 3.04; 95% CI, 1.49-6.18; P ¼ .002), lung
infection/consolidation (OR, 1.44; 95% CI, 1.02-2.02;
P ¼ .03). Smoking cessation did not significantly improve
other outcomes, however it was associated with a nonsig-
nificant trend toward a decreased risk for prolonged post-
operative length of stay (OR, 1.35; 95% CI, 0.85-3.91;
P ¼ .08) and in-hospital mortality (OR, 1.83; 95% CI,
0.85-3.91; P ¼ .1). On the other hand, patients who
stopped smoking at least 4 weeks before surgery achieved
results comparable with never smokers for all outcomes of
interest (Table 3).ery c August 2014
TABLE 2. Operative outcomes
Ex-smokers (N ¼ 3309) Never smokers (N ¼ 2164) Current smokers (N ¼ 640)
c2 P valuen % n % n %
Reintubation 142 4.31 81 3.75 33 5.2 .25
Full tracheostomy 53 1.61 32 1.48 17 2.68 .1
Lung infection/consolidation 456 13.8 283 13.1 108 17 .047
Main pulmonary complications 545 16.5 341 15.8 124 19.4 .1
Low output syndrome 800 24.2 564 26.1 150 23.5 .22
Real replacement therapy 136 4.13 115 5.33 27 4.23 .1
New cerebrovascular accident 32 0.977 27 1.25 13 2.04 .07
Reexploration for bleeding 147 4.47 82 3.8 24 3.77 .4
Sternal rewiring for instability 99 3.01 58 2.69 19 2.99 .77
Sternal wound infection 212 6.42 133 6.17 40 6.3 .9
Postoperative atrial fibrillation 751 22.7 443 20.5 103 16.2 .0007
Pleural effusion drained 155 4.69 97 4.49 33 5.17 .7
Prolonged hospital stay (10 d) 877 26.5 569 26.3 152 23.7 .4
Hospital death 61 1.87 51 2.38 17 2.71 .25
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cations was confirmed when patients who could not be de-
layed at least 4 weeks (classified as emergency or very
urgent cases) were excluded: all major pulmonary compli-
cations (OR, 1.50; 95% CI, 1.11-2.21; P ¼ .009), reintuba-
tion (OR, 1.90; 95% CI, 1.13-3.35; P ¼ .02), full
tracheotomy (OR, 2.96; 95% CI, 1.23-6.78; P ¼ .001),
and lung infection/consolidation (OR, 1.41; 95% CI,
1.01-2.25; P ¼ .04).
DISCUSSION
The main finding of the present study was that smoking
cessation at least 4 weeks before CABG reduced the risk
of major pulmonary complications including reintubation,
full tracheotomy, and lung infection/consolidation.
In the United States, approximately 8 to 10 million pro-
cedures requiring surgery and anesthesia are performed
on cigarette smokers.15 It has been estimated that if all pa-
tients were offered a smoking cessation intervention before
surgery, this could avoid 2 million complications, resulting
in large savings for both patients and health services.3
The deleterious effect of smoking after CABG has been
the subject of long-standing speculation.7 The beneficial ef-
fect of smoking cessation after CABG has been clearly
demonstrated.5,6 However, the effect of smoking cessation
before surgery on operative outcomes remains to be
determined. Several reports have confirmed that current
smoking has a deleterious effect on operative outcomes
compared with no smoking, In a multivariate analysis of
individuals more than 70 years old undergoing internal
thoracic artery grafting, He and colleagues8 reported a his-
tory of smoking (current and ex-smokers were compared
with never smokers) as an independent predictor of in-
patient mortality. Jones and colleagues9 demonstrated that
current smoking had the worst operative outcomes,
including pulmonary complications and operative death,The Journal of Thoracic and Cacompared with never smokers in 275 patients aged more
than 70 years. In a retrospective analysis of 2597 patients,
Al-Sarraf and colleagues10 reported that current smoking
was associated with an increased risk of pulmonary compli-
cations but not operative mortality compared with never
smoking. The investigators concluded that a smoking cessa-
tion period should be encouraged in smokers before
surgery.
This recommendation cannot be extrapolated from the
aforementioned studies as they demonstrated that current
smoking increased operative morbidity compared with non-
smokers, but the benefit from smoking cessation was not
demonstrated. The benefit from a short period of smoking
cessation on operative outcomes has only been shown by
a small prospective study from Warner and colleagues.11
On the other hand, Utley and colleagues12 have rejected
preoperative smoking as a predictor of outcomes in a large
retrospective study with 2916 patients. In this analysis,
however, patients were classified as either current smokers
or nonsmokers. Given that smokers are more likely to quit
around the time of surgery, the nonsmoking group is likely
to have included several smokers who recently quit.
In the absence of stronger evidence, current smoking
continues to be not perceived as a main risk factor by sur-
geons worldwide and smoking cessation programs are
commonly delayed until after surgery.
To the best of our knowledge, the present investigation
includes the largest sample size on the effect of smoking
cessation on operative outcomes.
In the present study, the crude incidence of postoperative
complications, including pulmonary complications, was not
significantly increased in current smokers compared with
ex-smokers and never smokers. This was partially because
of their better risk profile mostly related to younger age
(only 15% of current smokers were more than 70 years of
age compared with 40% among ex-smokers and neverrdiovascular Surgery c Volume 148, Number 2 471
FIGURE 1. Relationship between balance measure and number of interaction in the generalized boosted regressionmodeling for propensity score. Balance
measures were optimized with substantially fewer than 3000 iterations. ATT, Average treatment effect on the treated.
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ing analysis was able to demonstrate that smoking cessation
reduced the risk for all major pulmonary complications
(54% absolute risk decrease), including reintubation (2-
fold risk decrease), full tracheostomy (3-fold risk decrease),
and lung infection/consolidation (44% absolute risk
decrease). In addition, smoking cessation was associated
with a nonsignificant trend toward reduced risk of prolonged
postoperative length of hospital stay (38% absolute risk
decrease) and in-hospital mortality (83% absolute risk
decrease). Smoking cessation did not reduce the risk of other
operative complications such as pleural effusion requiring
drainage, postoperative stroke, need for renal replacement
therapy, POAF, sternal rewiring for instability, and SWI.
On the other hand, the operative outcomes of patients who
stopped smoking at least 4 weeks before surgery were com-
parable with the outcomes of patients who never smoked.
Although smoking cessation is an important health issue,
information about the underlying mechanisms of the effects
of smoking cessation on the lungs is surprisingly scarce.
Smoking cessation can result in a decrease in postoperative
pulmonary complications through physiologic improve-
ment in ciliary action, macrophage activity, and small472 The Journal of Thoracic and Cardiovascular Surgairway function as well as a decrease in sputum produc-
tion.16 In addition, an acute effect of smoking cessation
on inflammation is expected to play a main role. Previous
studies showed that macroscopic signs of chronic bronchitis
(edema, erythema, and mucus) decreased within 3 months
after smoking cessation, and totally disappeared after 6
months.17 In addition, exhaled nitric oxide levels increased
to almost normal values within 1 week of smoking cessa-
tion, suggesting that the smoke-induced inhibition of induc-
ible nitric oxide synthase production by epithelial cells is
reversible. A decrease in the number of macrophages in
sputum and bronchoalveolar lavage fluid has been shown
to be evident 1 to 2 months after smoking cessation. In addi-
tion, a decrease in proinflammatory mediator (soluble inter-
cellular adhesion molecules and soluble CD44) levels has
been reported.18
This study has some limitations. Despite the use of mul-
tinominal propensity weighting to minimize bias related to
different risk profiles, this remains a retrospective analysis
with known inherent limitations. Although smoking
cessation has been shown to reduce wound-related compli-
cations, wound healing time, and bone fusion time in or-
thopedic surgery,19,20 in the present study we wereery c August 2014
FIGURE 2. Propensity score distributions.
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rewiring for instability. We cannot exclude that smoking
cessation duration longer than 4 weeks may improve
sternal wound healing and prevent SWI. However, in the
present retrospective analysis, we were unable to
identify the optimum time to quit before surgery to
achieve maximum benefit; some previously published
research indicates a minimum of 6 to 8 weeks.15
The number of cigarette smoked per day or the number of
pack-years smoked was not recorded in the present study,
and the smoking status was determined from self-reportsTABLE 3. Average treatment effect on the treated (ATT) with patients wh
ATT for current smokers 95% CI
Reintubation 1.95 1.17-3.2
Full tracheostomy 3.04 1.49-6.1
Lung infection/consolidation 1.44 1.02-2.0
Main pulmonary complication 1.54 1.13-2.1
Low output syndrome 1.10 0.82-1.4
Real replacement therapy 1.28 0.72-2.2
New cerebrovascular accident 0.88 0.32-2.4
Reexploration for bleeding 0.89 0.47-1.6
Sternal rewiring for instability 1.25 0.68-2.2
Sternal wound infection 1.05 0.68-1.6
Postoperative atrial fibrillation 0.83 0.62-1.1
Pleural effusion drained 0.89 0.51-1.5
Prolonged hospital stay (10 d) 1.35 0.98-1.9
Hospital death 1.83 0.85-3.9
ATT, Average treatment effect on the treated; CI, confidence interval.
The Journal of Thoracic and Cawith no biochemical proof of the patients’ smoking habits.
However, self-reported smoking habits have been found to
be accurate in other studies.21
Within these acceptable limitations, the findings of the
present study strongly support the recommendation of at
least 4 weeks’ smoking cessation before nonurgent CABG
to improve postoperative outcomes and in particular to
reduce the risk of postoperative pulmonary complications.
However, all patients referred for CABG should be
encouraged to stop smoking at any time before surgery
because it is expected to be beneficial3; embarking on ao stopped smoking at least 4 weeks before surgery as reference
P value ATT for never smokers 95% CI P value
5 .01 0.88 0.62-1.25 .49
8 .002 0.97 0.55-1.72 .9
2 .03 1.06 0.86-1.30 .5
0 .006 1.04 0.86-1.26 .6
6 .5 1.15 0.99-1.35 .06
9 .39 1.3 0.96-1.75 .08
2 .8 1.02 0.55-1.90 .9
9 .73 0.79 0.58-1.09 .16
8 .46 0.82 0.56-1.20 .3
2 .8 0.86 0.66-1.10 .2
1 .2 0.88 0.76-1.03 .1
4 .68 0.99 0.75-1.35 .99
6 .08 0.99 0.85-1.14 .89
1 .1 1.16 0.74-1.83 .5
rdiovascular Surgery c Volume 148, Number 2 473
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Dsmoking cessation program should not be deferred until
after surgery.6
Smoking cessation services, which are limited at the
moment, should be developed to assist all prospective surgical
candidates. These results should help to guide treatment and
have the potential to improve outcomes and use of resources.References
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